CompletedPhase 2NCT04231981
Efficacy of INCMGA00012 in Penile Squamous Cell Carcinoma (ORPHEUS)
Studying Malignant tumor of penis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- MedSIR
- Principal Investigator
- Xavier García del MuroICO- Hospitalet
- Intervention
- Retifanlimab(drug)
- Enrollment
- 18 enrolled
- Eligibility
- 18 years · MALE
- Timeline
- 2020 – 2022
Study locations (13)
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano., Milan, Italy
- IRCCS Ospedale San Raffaele, Milan, Italy
- AUSL Reggio Emilia, Reggio Emilia, Italy
- Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- ICO-Hospitalet, L'Hospitalet de Llobregat, Spain
- Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain
- Hospital 12 de octubre, Madrid, Spain
- Hospital Clínico San Carlos, Madrid, Spain
- Hospital Virgen de la Arrixaca, Murcia, Spain
- Hospital Universitari Son Espases, Palma de Mallorca, Spain
- Hospital Virgen del Rocío, Seville, Spain
- Instituto Valenciano de Oncología, Valencia, Spain
- Hospital Miguel Servet, Zaragoza, Spain
Collaborators
Incyte Biosciences International Sàrl
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04231981 on ClinicalTrials.govOther trials for Malignant tumor of penis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07110038DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile CarcinomaInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- RECRUITINGPHASE2NCT06353906Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile CancerThe Netherlands Cancer Institute
- ACTIVE NOT RECRUITINGPHASE3NCT06465914A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese MalesShanghai Bovax Biotechnology Co., Ltd.
- ENROLLING BY INVITATIONNCT06565585Prediction of Local Recurrence and Its Impact on Long-term Outcomes After Low-risk Glans-sparing Surgery for Penile Squamous Cell CarcinomaUniversitaire Ziekenhuizen KU Leuven
- RECRUITINGPHASE2NCT06415318TIP Regimen Combined With Triplizumab Neoadjuvant Therapy for Locally Advanced Penile CancerSun Yat-sen University
- RECRUITINGPHASE1NCT05999396FIH, Bispecific CD276xCD3 Antibody CC-3 in Patients With Colorectal CancerGerman Cancer Research Center
- RECRUITINGPHASE2NCT06104618Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the PenisMayo Clinic
- RECRUITINGNANCT05899361A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of InterestDana-Farber Cancer Institute